Epilepsy is a devastating neurological disease affecting about 1 % of the population. Symptomatic treatment is achieved by pharmacological agents in approximately 70% of patients, and only for a small proportion of the remaining 30% there are non-pharmacological very efficacious alternatives such as surgical intervention. Therefore, there is a great unmet medical need for alternative treatment strategies.
In its preclinical program NsGene uses its proprietary EC BiodeliveryTM technology to deliver Galanin into the rat brain for suppression of epileptic seizures with the overall project goal to provide efficacy data and proof-of-concept for a clinical trial and further commercial development of an anti-epileptic EC BiodeliveryTM product.
Worldwide more than 50 million people suffer from some form of epilepsy
30% of the patients are refractory to conventional treatments
In 2007 global sales of drugs for treatment of epilepsy was more than 15 billion USD
